Second Sight Medical enters Singapore market, touts 1st procedure in region
Second Sight Medical (NSDQ:EYES) said today it entered the Singapore market with its Argus II retinal prosthesis system through its regional exclusive distribution partner Mandarin Opto-Medic.
The Sylmar, Calif.-based company said that its Argus II systems have been used in their first commercial procedure in the region, implanted last month in a 62-year-old patient with retinal degeneration at the Singapore National Eye Center by Dr. Edmund Wong and Dr. Laurence Lim with supervision from Dr. Emin Özmert.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s ...
Source: Mass Device - February 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Source Type: news
Second Sight touts 1st-in-human Orion cortical implant
Second Sight Medical (NSDQ:EYES) today announced the first trial implantation of its Orion cortical visual prosthesis system and updated on implantations of its Argus device and enrollment in an upcoming study.
The first implantation procedure was performed late last month by Dr. Nader Pouratian at the Ronald Reagan UCLA Medical Center, the Sylmar, Calif.-based company said, as part of an FDA-cleared feasibility trial it won approval to launch last November.
The Orion cortical visual prosthesis system is designed to convert images captured by a miniature video camera, mounted on a patient’s glasses, into a series of el...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Second Sight Source Type: news
GenSight to launch trial of gene therapy, visual stimulation device combo in UK
The UK’s Medicines and Healthcare Regulatory Agency has approved GenSight Biologics‘ (EPA:SIGHT) application to combine gene therapy and a wearable optronic visual stimulation device in patients with retinitis pigmentosa.
The first-in-man Phase I/II trial is designed to study the safety and tolerability of GenSight’s GS030 combination therapy in three groups of three patients each.
Get the full story at our sister site, Drug Delivery Business News.
The post GenSight to launch trial of gene therapy, visual stimulation device combo in UK appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat gensightbiologics Source Type: news
Commonalities in late stages of inherited blinding diseases suggest targets for therapy
(University of Pennsylvania) In studying the late stages of disease in two different canine models of retinitis pigmentosa, a group of progressive and inherited blinding diseases, University of Pennsylvania researchers found commonalities, specifically involving the innate immune system. The findings point to potential new treatment options for the conditions. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 20, 2017 Category: Biology Source Type: news
Second Sight launches Argus retinal prosthesis in Iran
Second Sight Medical (NSDQ:EYES) said today it launched its Argus II retinal prosthesis system in Iran, facilitated through its exclusive distribution partner Arshia Gostar Darman.
The Sylmar, Calif.-based company said that the system has been implanted in two patients in the country, with the procedures performed by Dr. Mohsen Farvadin at the Shiraz Pars Hospital and Khalili Hospital, Shiraz Medical Science University in 44-year old and 33-year old patients with retinitis pigmentosa.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with e...
Source: Mass Device - December 5, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Source Type: news
What is Usher Syndrome?
Discussion
Over 7000 diseases are considered rare disorders according to the National Organization for Rare Disorders® (NORD, rarediseases.org). NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. They have information on about 1200 rare diseases on their website (https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/).
Hearing loss (HL) is not rare and is a common problem across the ages. It affects 360 million people worldwide which is about 5% of the population. There are many causes of hearing loss an...
Source: PediatricEducation.org - October 23, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Pixium Vision wins French approval for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won approval from France’s regulatory agency to launch a feasibility clinical study of its next-gen Prima sub-retinal implant in patients with advanced dry age-related macular degeneration.
The Prima system is a next-gen wireless implant with a micro photovoltaic chip designed to be implanted under the retina to convert pulsed near-infra-red invisible light received from external glasses with an integrated mini-camera into electrical signals transmitted to the brain through the optic nerve, the company said.
The system is designed to treat retinal dystrophies with a focus on ad...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news
Second Sight wins go-ahead for German Argus II study in better-sighted RP patients
This study has the potential to change the management of patients with RP and, if successful, greatly expand the patient population who can benefit from this treatment, and for whom the Argus II could be a solution,” Dr. Walter of Germany’s Universitätsklinikum Aachen said in a prepared statement.
In July, Second Sight said its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia.
See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.
The post Second ...
Source: Mass Device - October 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Regulatory/Compliance Second Sight Source Type: news
Single gene injected into eye reverses type of blindness
Breakthrough made by Oxford researchers in treating retinitis pigmentosa, which affects 20,000 Britons. A single gene injected into the back of the eye was found to restore vision. (Source: the Mail online | Health)
Source: the Mail online | Health - October 2, 2017 Category: Consumer Health News Source Type: news
Keeping Calm in the OR: Ophthalmology Times
(MedPage Today) -- Also, approaches to promote cone regeneration in retinitis pigmentosa (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 19, 2017 Category: American Health Source Type: news
Second Sight Medical enters Russian market
Second Sight Medical (NSDQ:EYES) said today it entered the Russian market, with the 1st patient treated with its Argus II Retinal Prosthesis System in Moscow.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the Sylmar, Calif.-based company said.
The 1st implant was performed at the Federal State Institution & Clinical Research Center of the Federal Medico-Biological Agency at the end of June 2017 by a team of surgeons, with Dr. Paulo Stanga of the U...
Source: Mass Device - July 26, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic second-sight-medical Source Type: news
Second Sight Medical wins expanded CMS coverage for Argus II
Second Sight Medical (NSDQ:EYES) said today its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia.
With the expansion, the Sylmar, Calif.-based company said it’s Argus II device is now reimbursable in 7 of the 12 Medicare Administrative Contractor jurisdictions, covering the device in a total of 28 states, 2 territories and D.C.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which all...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic second-sight-medical Source Type: news
Gene mutation linked to retinitis pigmentosa in Southwestern US Hispanic families
(University of Texas Health Science Center at Houston) Thirty-six percent of Hispanic families in the U.S. with a common form of retinitis pigmentosa got the disease because they carry a mutation of the arrestin-1 gene, according to a new study from researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news
Boston man's bionic eye gives back sight to blind man
Anthony Andreottola, 56, was diagnosed with retinitis pigmentosa and was blind at 35 years old. The Boston man was finally able to see again with the help of a bionic eye surgery in 2015. (Source: the Mail online | Health)
Source: the Mail online | Health - June 16, 2017 Category: Consumer Health News Source Type: news
Bionic eye helps blind man see with "artificial vision"
A Boston man who lost his sight to the eye disease retinitis pigmentosa is getting a new look at the world with bionic eye technology. Paula Ebben of CBS Boston station WBZ reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 14, 2017 Category: Consumer Health News Source Type: news
